Recognition and Treatment of Hyperkalemia in Cardiometabolic Disease: Improving Care and Overcoming Challenges in Rural and Underserved Communities

Released On
February 28, 2022

Expires On
February 28, 2023

Media Type
Internet

Completion Time
60 minutes

Specialty
Acute Care, Cardiology, Critical Care, Emergency Medicine, Endocrinology, Geriatric Medicine, Hospitalist, Nephrology, Primary Care

Topic(s)
Acute Heart Failure, Cardiovascular Disease, Diabetes, Geriatric Medicine, Heart, Heart Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and RME Collaborative.

 

This activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Physicians — 1.0 ABIM MOC Point
  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

Program Overview

Hyperkalemia is a common electrolyte disorder associated with life-threatening cardiac arrhythmias and sudden death. In patients who have heart failure, chronic kidney disease, or diabetes mellitus or who use renin-angiotensin-aldosterone system inhibitors (RAASi), there is a particularly increased risk of chronic or recurrent hyperkalemia. Hyperkalemia is often a reason for the suboptimal dosing or complete discontinuation of RAASi. Despite recent treatment advances, hyperkalemia remains a challenge for primary care clinicians, especially in rural and underserved communities where access to care is limited. In this CME/CE activity, expert faculty will review key predictors for hyperkalemia, clinical evidence for new potassium-binding agents, and individualized approaches to management. Strategies to improve team-based care in rural and underserved settings will also be discussed.

This enduring activity is a recorded session from the 3rd Annual Rural Health Clinical Congress that took place on November 20, 2021.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients with or at risk for hyperkalemia based on the presence of risk factors
  • Evaluate the efficacy and safety of new treatments for hyperkalemia
  • Develop a treatment plan for patients with hyperkalemia based on the latest guideline recommendations, clinical evidence, and patient characteristics
  • Employ a multidisciplinary team-based approach to improve the management of hyperkalemia in rural and underserved areas

Faculty

FACULTY_NAME

Akshay S. Desai, MD, MPH

Associate Professor
Harvard Medical School
Director, Cardiomyopathy and Heart Failure Program
Brigham and Women’s Hospital
Boston, MA

FACULTY_NAME

Dana E. King, MD (Moderator)

Clinical Provider
Atrium Health, Wake Forest Baptist
Winston-Salem, NC


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For physicians claiming ABIM MOC points, your information will be shared through the ACCME’s Program and Activity Reporting System (PARS). Please allow approximately 30 days for your MOC points to appear on your ABIM records.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Akshay S. Desai, MD, MPH, has disclosed the following relationships: grant/research support from Abbott, Alnylam Pharmaceuticals, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, and Novartis Pharmaceuticals Corporation; and consultant for Abbott, Alnylam Pharmaceuticals, Inc., Amgen, Inc., AstraZeneca Pharmaceuticals, Bayer Corporation, Biofourmis, Inc., Boehringer-Ingelheim, Boston Scientific Corporation, Cytokinetics, Inc., DalCor Pharmaceuticals, Lexicon Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis Pharmaceutical Corporation, Regeneron Pharmaceuticals, Inc., Relypsa, Inc., Sun Pharmaceutical Industries, Ltd., and Verily Life Sciences.

Dana E. King, MD, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer

The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME/CE credit participants must:

  1. Read the CME/CE information, including learning objectives and disclosure statements.
  2. Complete the pre-test.
  3. View the online activity.
  4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

For Physicians Claiming ABIM MOC Credit
To obtain MOC credit, you must provide your ABIM number and DOB (MM/DD) in the activity evaluation form.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC 2022. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

General Questions
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or cme@cmeruralhealth.com.

Accreditation Support
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at inquiries@pimed.com.